Replies to post #283863 on NorthWest Biotherapeutics Inc (NWBO)

[JRIII]

But it can be replaced to "additional endpoints" since PFS is not a good indicator in immunotherapy

Sure it can! In fact, let's just replace all the bad stuff with good stuff. There, that fixed it! No more of that problematic bad stuff. And clearly they didn't mean it when they set pfs as the primary indicator of the trial, since "PFS is not a good indicator in immunotherapy." Must have been one of those notorious NWBO lapses to set something that's "not a good indicator in immunotherapy" as the primary indicator of an immunotherapy trial.